In This Article:
As we approach the end of 2024, global markets have shown mixed signals with major U.S. stock indexes like the Nasdaq Composite experiencing moderate gains, although recent declines in consumer confidence and durable goods orders have raised concerns about economic stability. In this environment, high growth tech stocks are particularly intriguing due to their potential to capitalize on innovation and adaptability amidst fluctuating market conditions.
Top 10 High Growth Tech Companies
Name | Revenue Growth | Earnings Growth | Growth Rating |
---|---|---|---|
eWeLLLtd | 26.41% | 28.82% | ★★★★★★ |
Waystream Holding | 22.09% | 113.25% | ★★★★★★ |
Pharma Mar | 25.43% | 56.19% | ★★★★★★ |
Sarepta Therapeutics | 24.07% | 43.17% | ★★★★★★ |
CD Projekt | 24.92% | 27.00% | ★★★★★★ |
TG Therapeutics | 34.86% | 56.98% | ★★★★★★ |
Fine M-TecLTD | 36.52% | 131.08% | ★★★★★★ |
Alkami Technology | 21.99% | 102.65% | ★★★★★★ |
Elliptic Laboratories | 70.09% | 111.37% | ★★★★★★ |
Travere Therapeutics | 31.70% | 72.51% | ★★★★★★ |
Click here to see the full list of 1270 stocks from our High Growth Tech and AI Stocks screener.
Let's uncover some gems from our specialized screener.
Vitrolife
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Vitrolife AB (publ) specializes in providing products for assisted reproduction and has a market capitalization of approximately SEK29.81 billion.
Operations: Vitrolife generates revenue through three primary segments: Genetics (SEK1.23 billion), Consumables (SEK1.61 billion), and Technologies (SEK721 million).
Vitrolife, amidst executive shifts and active conference participation, reported a slight dip in third-quarter net income to SEK 116 million from SEK 122 million year-over-year, despite a revenue increase to SEK 867 million. This scenario underscores a resilience in sales growth but highlights challenges in profit retention. The company's commitment to innovation is evident as it navigates through leadership transitions and strategic presentations at major healthcare conferences. With an expected annual revenue growth of 8.2%, Vitrolife is outpacing the Swedish market's growth of 1.2%, yet it faces hurdles to achieving profitability within three years—a testament to its potential tempered by immediate financial realities.
-
Navigate through the intricacies of Vitrolife with our comprehensive health report here.
-
Examine Vitrolife's past performance report to understand how it has performed in the past.
Jonhon Optronic Technology
Simply Wall St Growth Rating: ★★★★☆☆
Overview: Jonhon Optronic Technology Co., Ltd. focuses on the research and development of optical, electrical, and fluid connection technologies and equipment in China, with a market cap of CN¥84.34 billion.